MedPath

Irbesartan

Generic Name
Irbesartan
Brand Names
Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
Drug Type
Small Molecule
Chemical Formula
C25H28N6O
CAS Number
138402-11-6
Unique Ingredient Identifier
J0E2756Z7N
Background

Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.

Irbesartan was granted FDA approval on 30 September 1997.

Indication

Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.

Associated Conditions
Diabetic Nephropathy, Hypertension
Clinical Trials
Related News

Travere Therapeutics Plans sNDA Submission for FILSPARI to Treat Rare Kidney Disease FSGS

• Travere Therapeutics has completed a Type C meeting with the FDA and plans to submit a supplemental New Drug Application for FILSPARI to treat focal segmental glomerulosclerosis by Q1 2025. • If approved, FILSPARI would become the first FDA-approved treatment for FSGS, a rare kidney disorder affecting over 40,000 patients in the U.S. that can lead to kidney failure. • The sNDA submission will be based on data from the Phase 3 DUPLEX and Phase 2 DUET studies, supported by recent PARASOL workgroup findings linking proteinuria reduction to improved kidney outcomes.

Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised

• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million. • Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth. • The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS. • Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.

FDA Grants Full Approval to Travere's Filspari for IgA Nephropathy

• The FDA granted full approval to Travere Therapeutics' Filspari (sparsentan) for IgA nephropathy, allowing broader use for patients at risk of disease progression. • The approval was based on the PROTECT study, which demonstrated Filspari significantly slowed kidney function decline over two years compared to irbesartan. • Filspari is now positioned as a foundational, non-immunosuppressive treatment option, potentially replacing the current standard of care for IgAN patients. • The label update removes a specific urine protein level requirement, expanding the eligible patient population and increasing Filspari's market potential.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy